Insider Cluster (3 insiders) ·Filed Jun 5, 2026

UTHR

UNITED THERAPEUTICS Corp
NEUTRAL
Impact 2/10
Horizonimmediate Processed3mo ago
Insider cluster: 3 insiders, $0.4M total
Actionable Insight • Neutral

These sales are routine tax- and liquidity-driven dispositions following option exercises. No bearish signal — ignore. Monitor next 10-Q for any fundamental changes, but this cluster has no trading implications.

DirectionNeutral
Confidencehigh
Horizonimmediate
Final — all horizons settled through T+60d ⚠ clustered
UTHR ▼ -6.30% at T+60d
NEUTRAL call ✗ call lost -6.30% · α vs SPY -9.36% · entry $544.69 → $510.35
Entry anchored
Jun 5, 2026
via day open
T+1d
+1.55%
call +1.55% · α +1.84%
$553.14
settled 4mo ago
T+5d
+0.90%
call +0.90% · α -1.22%
$549.57
settled 4mo ago
T+20d
+0.47%
call +0.47% · α -1.16%
$547.25
settled 3mo ago
T+60d
-6.30%
call -6.30% · α -9.36%
$510.35
settled 4w ago

Price Chart

Loading chart...

Executive Summary

Three top insiders at United Therapeutics (CEO, CFO, General Counsel) sold a total of $391K in open-market shares over a 2-day period (June 3-4, 2026). These sales are trivial relative to the $23.2B market cap (0.0017%), are part of a broader cluster of option exercises and same-day sales that appear to be tax- and liquidity-driven, and carry no material informational signal.

Key Financial Metrics

Direction
selling
Total Value
$391.0K
Insiders
3

Key Facts

  • CEO Martine Rothblatt sold 401 shares for ~$218K on June 3, 2026
  • EVP & General Counsel Paul Mahon sold 200 shares for ~$108K on June 4, 2026
  • CFO James Edgemond sold 120 shares for ~$65K on June 4, 2026
  • Total open-market sales: $391K, representing 0.0017% of $23.2B market cap
  • All three insiders concurrently exercised large option tranches (CEO: 28,500 shares; CFO: 20,000 shares; GC: 8,300 shares) — sales are clearly tax-cover and liquidity-driven
  • No insider open-market purchases in the cluster

Financial Impact

Total insider sales of $391K are negligible relative to $23.2B market cap (0.0017%)

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
77% bullish (22 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-UTHR-1780691656614
91 reports for UTHR
Performance horizon
80% Hit rate 4 of 5 directional calls best @ T+60▲ +5.53%Feb 25, 2026
Filters
Rows
Reports for UTHR — sortable, filterable
TypeNow
Sep 15, 2026
17d ago
Insider Cluster
NEUTRAL ★ 2/10
$500.35 $497.31▼ −0.61%▼ −2.72%$541.70 (+8.26%)
Sep 11, 2026
21d ago
Insider Cluster
NEUTRAL ★ 3/10
$497.11 $494.63▼ −0.50%▼ −0.28%$541.70 (+8.97%)
Sep 10, 2026
22d ago
Insider Cluster
MIXED ★ 4/10
$503.86 $497.27▼ −1.31%▼ −0.81%$541.70 (+7.51%)
Sep 9, 2026
23d ago
Insider Cluster
NEUTRAL ★ 3/10
$506.82 $498.48▼ −1.65%▼ −0.99%$541.70 (+6.88%)
Sep 4, 2026
28d ago
Insider Cluster
NEUTRAL ★ 2/10
$487.61 $502.70▲ +3.09%▲ +4.30%$541.70 (+11.09%)
Sep 3, 2026
29d ago
Insider Cluster
NEUTRAL ★ 2/10
$488.16 $497.11▲ +1.83%▲ +2.98%$541.70 (+10.97%)
Aug 28, 2026
5w ago
Insider Cluster
NEUTRAL ★ 2/10
$515.46 $487.61▼ −5.40%▼ −5.51%$541.70 (+5.09%)
Aug 27, 2026
5w ago
Insider Cluster
NEUTRAL ★ 2/10
$527.91 $492.02▼ −6.80%▼ −6.03%$541.70 (+2.61%)
Aug 26, 2026
5w ago
Insider Cluster
NEUTRAL ★ 3/10
$516.68 $492.02▼ −4.77%▼ −4.65%$541.70 (+4.84%)
Aug 25, 2026
5w ago
Insider Cluster
NEUTRAL ★ 2/10
$516.68 $492.02▼ −4.77%▼ −4.65%$541.70 (+4.84%)
Showing 10 of 91

US Market Status

Market Closed — Opens Mon (64h 9m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published Jun 5, 2026